Please login to the form below

Not currently logged in
Email:
Password:

Mirna Therapeutics appoints new executive vice president

Miguel Barbosa willalso serve as chief scientific officer

Mirna Therapeutics has appointed Dr Miguel Barbosa as executive vice president and chief scientific officer.

Mirna Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics.

Barbosa joined the company with 20 years of biopharmaceutical research discovery experience and for the past decade has served in senior leadership roles at Johnson & Johnson subsidiaries.

Paul Lammers, Mirna's president and chief executive officer, said: “We are pleased to welcome Miguel to the role of chief scientific officer.

As a highly accomplished industry executive with a proven ability to lead top research and development programs, we are confident Miguel's expertise and strategic vision, particularly in emerging areas of science, will prove critical as we advance our pipeline of microRNA-based oncology therapeutics.”

30th October 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics